EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Interim decision making in seamless trial designs: An application in an adaptive dose‐finding study in a rare kidney disease

Olympia Papachristofi iD, Björn Bornkamp iD, Melanie Wright iD, Tim Friede iD

Pharmaceutical Statistics · 2024-01 · 23 (1) · 20-30

DOI: 10.1002/pst.2335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 11.09.2023. Verfasst von Olympia Papachristofi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Kidney Diseases, Research Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adaptive seamless trial designs, combining the learning and confirming cycles of drug development in a single trial, have gained popularity in recent years. Adaptations may include dose selection, sample size re‐estimation and enrichment of the study population. Despite methodological advances and recognition of the potential efficiency gains such designs offer, their implementation, including how to enable efficient decision making on the adaptations in interim analyzes, remains a key challenge in their adoption. This manuscript uses a case study of an adaptive seamless proof‐of‐concept (Phase 2a)/dose‐finding (Phase 2b) to showcase potential adaptive features that can be implemented in trial designs at earlier development stages and the role of simulations in assessing the design operating characteristics and specifying the decision rules for the adaptations. It further outlines the elements needed to support successful interim analysis decision making on the adaptations while safeguarding study integrity, including the role of different stakeholders, interactive simulation‐based tools to facilitate decision making and operational aspects requiring preplanning. The benefits of the adaptive Phase 2a/2b design chosen compared to following the traditional two separate studies (2a and 2b) paradigm are discussed. With careful planning and appreciation of their complexity and components needed for their implementation, seamless adaptive designs have the potential to yield significant savings both in terms of time and resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney DiseasesResearch DesignHumansComputer SimulationDecision MakingSample SizeClinical Trials as Topic

Stichwörter der Autor:innen

IgA nephropathyadaptive designsdata monitoring committeedose-findingproof-of-conceptsimulations

Autor:innen und Institutionen

  • Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland.
  • Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.

ORCID-Profile: Olympia Papachristofi, Björn Bornkamp, Melanie Wright, Tim Friede

Förderung

  • Novartis Pharma AG

Zitieren

APA

Papachristofi, O., Bornkamp, B., Wright, M., & Friede, T. (2024). Interim decision making in seamless trial designs: An application in an adaptive dose‐finding study in a rare kidney disease. Pharmaceutical Statistics, 23(1), 20-30. https://doi.org/10.1002/pst.2335

Vancouver

Papachristofi O, Bornkamp B, Wright M, Friede T. Interim decision making in seamless trial designs: An application in an adaptive dose‐finding study in a rare kidney disease. Pharmaceutical Statistics. 2024;23(1):20-30. doi:10.1002/pst.2335

BibTeX
@article{Papachristofi2024,
  author = {Papachristofi, Olympia and Bornkamp, Björn and Wright, Melanie and Friede, Tim},
  title = {Interim decision making in seamless trial designs: An application in an adaptive dose‐finding study in a rare kidney disease},
  journal = {Pharmaceutical Statistics},
  year = {2024},
  volume = {23},
  number = {1},
  pages = {20--30},
  doi = {10.1002/pst.2335}
}
Kostenlos starten →